Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
8 August 2016 |
Main ID: |
NCT01659138 |
Date of registration:
|
03/08/2012 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis
FUSCIA |
Scientific title:
|
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Efficacy and Safety of SAR339658 in Patients With Active Moderate to Severe Ulcerative Colitis (UC) |
Date of first enrolment:
|
August 2012 |
Target sample size:
|
28 |
Recruitment status: |
Terminated |
URL:
|
https://clinicaltrials.gov/show/NCT01659138 |
Study type:
|
Interventional |
Study design:
|
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
|
Phase:
|
Phase 2
|
|
Countries of recruitment
|
Austria
|
Belgium
|
Canada
|
France
|
Germany
|
Italy
|
Poland
|
United States
|
Contacts
|
Name:
|
Clinical Sciences & Operations |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Sanofi |
| | |
Key inclusion & exclusion criteria
|
Inclusion criteria:
- Male or Female =18 and =70 years old
- History of active ulcerative colitis of at least 3 months duration
- Active UC should be confirmed by colonoscopy or flexible sigmoidoscopy during the
screening period within 7 days prior to randomization.
- Moderate to severe ulcerative colitis at time of screening, confirmed by Mayo score
=6 to 12 and endoscopy subscore of =2 despite treatment with immunosuppressants
and/or anti-tumor necrosis factors (TNFs):
- Immunosuppressants: Patient must be on concurrent treatment with or have had an
inadequate response to (did not respond to or lost response to) or be intolerant
to immunosuppressants such as azathioprine, 6-mercaptopurine, or methotrexate.
- AND/OR
- TNF-alpha antagonists: Patient must have had an inadequate response or lost
response or be intolerant to TNF-alpha antagonists
- Fecal calprotectin =200mg/kg
- Patients on corticosteroids must be on a stable dose =2 weeks prior to screening
- Patients on azathioprine, 6- mercaptopurine or methotrexate must be on treatment for
at least 12 weeks prior to screening; and on a stable dose =4 weeks prior to
screening
- Patients on oral 5-aminosalicylates, mesalamine or sulfasalazine must be on a stable
dose for =4 weeks prior to screening
- Patients naïve to anti-TNF alpha or non-responder (primary or secondary) or
intolerant to anti-TNF alpha
- Signed written informed consent
Exclusion criteria:
- Patients with Crohn's Disease
- Diagnosis of indeterminate colitis
- Patients with stool sample positive for ova, parasites, or positive culture for
aerobic pathogens including: Aeromonas, Plesiomonas, Shigella, Yersinia,
Campylobacter and E. Coli spp. or positive for Clostridium difficile B toxin in
stools.
- Patients with prior colectomy or anticipated colectomy during their participation in
the study
- Presence of ileal pouch or ostomy
- Fulminant disease or toxic megacolon
- Colonic dysplasia except for adenoma
- Total Parenteral Nutrition
- Cyclosporine, mycophenolate mofetil, sirolimus (rapamycin), thalidomide or tacrolimus
within 2 months prior to screening
- Previous exposure to natalizumab (Tysabri®) or vedolizumab
- Antidiarrheals within 2 weeks prior to screening
- Prednisone >40 mg/day (or equivalent)
- Budesonide >9 mg/day
- Received intravenous corticosteroids within 2 weeks prior to screening or during
screening
- Rectally administered topical 5-aminosalicylate or corticosteroids within 4 weeks
prior to screening
- Received therapeutic enema or suppository, other than required for colonoscopy or
flexible sigmoidoscopy within 4 weeks prior to screening or during screening
- Antibiotics for ulcerative colitis or gastrointestinal infection within 4 weeks prior
to screening
- Patient who has previously participated in any clinical trial of GBR500 / SAR339658
- Patient who has taken other investigational medications within 2 months or 5 half
lives, (whichever is longer) prior to screening
- Use of any biologics for the treatment of ulcerative colitis in the previous 8 weeks
before screening
- Requirement for concomitant treatment that could bias primary evaluation
- Pregnant or breast-feeding women
- Women of childbearing potential not protected by highly effective contraceptive
method of birth control
- Patient with latent or active tuberculosis (TB) defined as:
- Any signs or symptoms suggestive of active TB upon medical history or clinical
examination
- Patients with a positive QuantiFERON TB Gold Test
- Chest radiograph within 3 months prior to the inclusion visit consistent with
prior tuberculosis infection including, but not limited to, apical scarring,
apical fibrosis, or multiple calcified granulomasa. This does not include
non-caseating granulomasa
- Patients with close contact with a person with active tuberculosis
- Patient with a history of listeriosis or tuberculosis (unless it is documented that
they were adequately treated)
- Administration of any live (attenuated) vaccine within 3 months prior to the
screening Visit (eg, varicella-zoster vaccine, oral polio, rabies)
- Positive Hepatitis B surface antigen (HBsAg) or positive Hepatitis B core antibody
(HBcAb); and/or positive Hepatitis C antibody (HCV) at the Screening Visit
- Prior opportunistic infections within 6 months prior to screening or while receiving
anti-TNF treatment
- History of a hypersensitivity reaction, other than localized injection site reaction,
to any biological molecule
- History or any current signs of demyelinating disease or any neurological disease
that can by the opinion of Investigator interfere with study safety assessments
including assessment for progressive multifocal leukoencephalopathy
- Patients with bleeding disorders or known platelet dysfunction
The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.
Age minimum:
18 Years
Age maximum:
70 Years
Gender:
Both
|
Health Condition(s) or Problem(s) studied
|
Ulcerative Colitis
|
Intervention(s)
|
Drug: SAR339658
|
Other: Placebo
|
Primary Outcome(s)
|
Proportion of Participants with Clinical Response by Mayo Score
[Time Frame: At Week 8]
|
Secondary Outcome(s)
|
Number of Participants with adverse events
[Time Frame: Up to Week 17]
|
Change from Baseline in the partial Mayo Score
[Time Frame: At Weeks 4 and 6]
|
Change from Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ)
[Time Frame: At Weeks 4 and 8]
|
Change from Baseline in Quality of Life (QoL) SF-36
[Time Frame: At Weeks 4 and 8]
|
Proportion of Participants with Clinical Remission by Mayo Score
[Time Frame: At Week 8]
|
Proportion of Participants with Mucosal Healing
[Time Frame: At Week 8]
|
Secondary ID(s)
|
2012-002013-19
|
ACT12688
|
U1111-1124-1076
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|